Is Protein in My Urine After Starting Penicillamine a Kidney Side Effect?
Proteinuria after starting penicillamine is most likely a drug side effect — a known complication — rather than Wilson disease damaging your kidneys; your doctor needs to know so they can decide whether to continue, reduce the dose, or switch medications.
Finding protein in your urine after starting penicillamine is unsettling, and the first question is an obvious one: is this the disease attacking my kidneys, or is it the medication? In most cases, for a patient who has just started or recently increased penicillamine, the answer is that the drug is the most likely culprit. Proteinuria is one of penicillamine’s best-known side effects, and it requires prompt assessment — but it does not automatically mean you need to stop treatment entirely.
Two Possible Causes — and How to Think About Them
Possibility 1: Wilson disease affecting the kidneys
Wilson disease can involve the kidneys independently of any medication. Excess copper can deposit in the renal tubules — the microscopic tubes in the kidney that filter and reabsorb various substances — causing a condition called Fanconi syndrome or, more generally, renal tubular dysfunction.1 When tubular cells are copper-damaged, the kidney loses the ability to properly reabsorb small proteins, amino acids, glucose, and other molecules. The result can include mild proteinuria (protein in the urine), along with other markers of tubular dysfunction such as glycosuria (glucose in the urine despite normal blood sugar) or aminoaciduria.
This type of kidney involvement is a direct effect of the disease itself — it tends to be present at diagnosis and typically improves as copper is brought under control.2
Possibility 2: Penicillamine nephrotoxicity
Penicillamine is associated with a different pattern of kidney involvement — an immune-mediated damage to the glomeruli (the kidney’s filtering units) that can cause proteinuria, sometimes significantly. This is called drug-induced membranous nephropathy or glomerulonephritis.3 Unlike disease-related tubular dysfunction, this side effect:
- Typically appears weeks to months after starting penicillamine, not at diagnosis
- Can cause substantial protein loss in the urine, sometimes rising into nephrotic-range levels
- Is unrelated to the severity of Wilson disease itself
- Usually resolves or improves when penicillamine is dose-reduced or stopped
The timing of your proteinuria is the key diagnostic clue. If protein in the urine appeared or worsened after you started penicillamine — not before — drug side effect is the primary concern.
How Serious Is Penicillamine-Related Proteinuria?
The severity matters a great deal. Your doctor will assess the level of protein and the type:
| Urine protein level | Typical interpretation |
|---|---|
| Trace or small amount | May be acceptable with close monitoring; some guidelines allow continuation |
| Moderate, rising | Requires decision: dose reduction, close follow-up, or switch medications |
| Nephrotic range (large) | Penicillamine usually must be stopped; kidney biopsy may be needed to characterize the damage |
The 2022 AASLD Practice Guidance recommends regular urine monitoring (typically dipstick urine protein checks at each clinic visit) specifically because proteinuria is a known and important complication of penicillamine therapy.4 If your urine protein was not being checked before you started the medication and at regular intervals since, that monitoring should begin now.
What Will Your Doctor Do?
The management depends on the degree of proteinuria and whether it is rising or stable:
-
Quantify it precisely. A spot urine protein-to-creatinine ratio or a 24-hour urine protein collection gives a more reliable number than a dipstick alone.
-
Look for other signs of tubular versus glomerular damage. A comprehensive urinalysis can help distinguish whether the problem is in the tubules (disease-related) or the glomeruli (drug-related). Urine microscopy may show casts or other cellular elements.
-
Compare to any pre-treatment baseline. If protein was present in your urine before you started penicillamine, the picture is more complex — the disease may be contributing.
-
Consider dose adjustment or medication switch. Reducing the penicillamine dose often improves drug-related proteinuria. If the protein is substantial or continues to rise, switching to trientine (another copper chelator with a more favorable kidney side-effect profile) is a well-established option.5 Zinc is also an alternative for some patients and does not carry the same kidney risk.6
-
Monitor kidney function tests. Serum creatinine and estimated glomerular filtration rate (eGFR) should be checked alongside urine protein. Proteinuria with normal kidney function is managed differently from proteinuria with rising creatinine.
Should You Stop Penicillamine on Your Own?
No. Do not stop or reduce penicillamine without discussing it with your prescribing physician first. Even if the drug is causing a kidney problem, abruptly stopping copper-lowering treatment can cause a rapid increase in copper levels — which carries its own serious risks, including neurological deterioration.7 The decision about whether to continue, reduce, or switch needs to weigh the kidney side effect against the risk of uncontrolled copper.
Contact your hepatologist or specialist as soon as you notice an abnormal urine result, rather than waiting until the next scheduled appointment. Most clinics will want to see a trend in the protein level (is it stable, rising, or falling?) and will act based on that pattern.
Monitoring Going Forward
Regardless of what your team decides, you should expect routine urine protein monitoring to become a regular part of your follow-up — at least until the situation is stable and resolved. If you switch to trientine, be aware that it requires its own monitoring, though the kidney risk profile is more favorable.5
The general expectation for kidney involvement due to Wilson disease is that it improves as copper is controlled. Drug-related kidney effects are expected to resolve when the offending drug is dose-reduced or stopped. Either way, the trajectory should be toward improvement once the correct management is in place.
For more context on how penicillamine compares to other treatment options, see medications overview, and for what information to bring to your next appointment, see what to tell your doctor.
The information here is patient education only. Proteinuria is a clinical finding that requires a physician’s evaluation — do not use this page to make medication decisions. If you are concerned about your urine test results, contact your treating specialist.
References
-
Czlonkowska, Anna, Tomasz Litwin, Piotr Dusek, Peter Ferenci, Rajiv Bhatt, Michael L. Schilsky, and Karl Heinz Weiss. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. ↩
-
European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩
-
DeSilva, M. H., and C. J. Eastmond. “Management of Proteinuria Secondary to Penicillamine Therapy in Rheumatoid Arthritis.” Clinical Rheumatology 11, no. 3 (1992): 371–374. https://doi.org/10.1007/bf02207960. ↩
-
Schilsky, Michael L., Karl Heinz Weiss, Eve A. Roberts, et al. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 4 (2022): 1428–1452. https://doi.org/10.1002/hep.32801. ↩
-
Weiss, Karl Heinz, Jan Pfeiffenberger, Wolfgang Stremmel, and Julia Estall. “Prospective Study to Assess Long-Term Outcomes of Treatment with Trientine in Wilson Disease Patients.” Journal of Hepatology 64, Suppl 2 (2016): S764. https://doi.org/10.1016/s0168-8278(16)00368-8. ↩↩
-
Alkhouri, Naim, and Michael L. Schilsky. “Wilson Disease: A Summary of the Updated AASLD Practice Guidance.” Hepatology Communications 7, no. 6 (2023): e0150. https://doi.org/10.1097/HC9.0000000000000150. ↩
-
Kalita, Jayantee, Uday Kumar Misra, Sanjay Chandra, and Maneesh Kumar. “Worsening of Wilson Disease Following Penicillamine Therapy.” European Neurology 70, no. 5–6 (2013): 345–350. https://doi.org/10.1159/000355276. ↩
-
Kumar, Ramesh, Velayutham Murugan, Peter N. Lionel, and Anand Thomas. “Management of Children and Adolescents with Wilson Disease and Neurological Worsening Following D-Penicillamine.” Annals of Indian Academy of Neurology 25, no. 3 (2022): 519–525. https://doi.org/10.4103/aian.aian_519_21. ↩
यह मरीज़ शिक्षा है, न कि चिकित्सा सलाह। अपनी देखभाल से जुड़े किसी भी निर्णय के लिए हमेशा अपनी डॉक्टर टीम से बात करें।